Valeant tanks on short report; 23andMe gets back into health testing;

@FierceBiotech: Novartis inks a string of deals to widen its immuno-oncology arsenal. Article | Follow @FierceBiotech

@JohnCFierce: $AZN's lesinurad is a mess. Safety issues, efficacy ???. Another test for the 'new' FDA. I suspect it gets approved. News | Follow @JohnCFierce

@DamianFierce: $BIIB things I forgot to mention:U.S. royalties on $RHBBY's ocrelizumab are 13.5% to 24%--STX-100 not affected by fibrosis cuts. | Follow @DamianFierce

> Valeant Pharmaceuticals ($VRX) watched its share price plummet more than 20% on Wednesday as a report from a short seller compounded existing worries about the company's business model. News

> 23andMe resumed offering health information through its consumer-targeting spit tests, working its way back to the market after running into issues with the FDA in 2013. More

> Gilead Sciences ($GILD) provided doses of its early-stage treatment for Ebola virus to a patient in the U.K. through a compassionate access program. Item

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: Fierce 15 co. Shockwave Medical aims to deploy energy-delivering balloons in the peripheral and coronary arteries. More | Follow @VarunSaxena2

@EmilyWFierce: Discovery of the day: Former "Daria" director illustrated and directed $PFE's Zoloft sad blob commercials. More | Follow @EmilyWFierce

> American Cancer Society guidelines updated to recommend fewer mammograms. Item

> Rheonix bags $28M for molecular testing platforms. Report

Pharma News

@FiercePharma: Michigan governor urges Perrigo shareholders to reject Mylan's offer. Story | Follow @FiercePharma

@CarlyHFierce: Good news for Allergan: Men want to treat wrinkles. Bad? They're clueless about products. Story | Follow @CarlyHFierce

> Teva mulls $7B stock offering to help fund Allergan generics buy. More

> Clinton urges FDA, FTC to take action against questionable pharma pricing. News

Biotech Research News

> King's College team IDs a gene target for Parkinson's. Report

> Georgetown researchers flag success of pilot Parkinson's drug study. More

> Gene therapy for brain protein boosts memory in aged mice. Article

> RIKEN mouse study sheds new light on depression. Item

> MicroRNA controls tissue-specific PTEN expression in brain cancer. Story

Vaccines News

> Sanofi, Gates Foundation and IDRI team up to improve vaccine development process. News

> Cancer vaccines field sees new player emerge with Gritstone's $102M Series A. More

> Inovio's MERS vaccine could hit PhI before year's end. Story

> CSL to buy back $723M of its shares. Item

> Genocea puts pneumococcal vaccine on back burner following PhII failure. Article

Pharma Marketing News

> Good news for Allergan: Men want to treat wrinkles. Bad? They're clueless about products. Story

> PCSK9 drugmakers go Big Data to ID more eligible patients. Report

> Relypsa, Sanofi marketing teams revved up and waiting for FDA nod on patiromer. Article

> AstraZeneca touts new Russian plant as boon for emerging markets sales. Item

> Angling for more reach with providers, Merck melds Univadis unit with Physicians Interactive. More

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.